EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 909 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate February 20, 2026 Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... February 11, 2025 Managing Side Effects with South Asian Foods July 19, 2022 Lung Cancer Treatment Research Enters a New Era October 17, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tepotinib What Happens If More People Get Screened for Cancer? Why consistent and funded cancer policies are key to improving cancer... What Is Pancreatic Enzyme Replacement Therapy in Cancer Care?
